Lori T. Raetzman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lori T. Raetzman has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
Karen E. Weis
University of Illinois at Urbana-Champaign
8 shared publicationsAshley D. Himes
Department of Molecular and Integrative Physiology (L.B.N., A.D.H., D.R.G., L.T.R.), University of Illinois at Urbana-Champaign, Urbana, Illinois 61801
4 shared publications- Jodi Anne Flaws
Department of Comparative Biosciences, University of Illinois Urbana-Champaign , Urbana, IL 61802
4 shared publications Karen Weis
Department of Molecular and Integrative Physiology, University of Illinois Urbana-Champaign , Urbana, IL 61801
4 shared publicationsPaven K. Aujla
Neuroscience Program University of Illinois at Urbana‐Champaign Urbana Illinois
4 shared publications- Xiyu Ge
Center for Precision Environmental Health, Baylor College of Medicine, Houston, TX 77030, USA
4 shared publications
Latest Publications
- Open Access
- 15 July 2026
- Published by The Endocrine Society in Endocrine Reviews
Genetic and environmental drivers of craniofacial, brain, and pituitary disorders
Congenital pituitary hormone deficiency (CH) is a rare disorder that usually involves deficient production of growth hormone (GH) and other pituitary hormones. Many cases are syndromic, affecting other aspects of craniofacial development and sometimes other organs. There are many genes implicated in congenital pituitary hormone deficiency, and some of them also cause more severe disorders like septo-optic dysplasia (SOD) and holoprosencephaly (HPE). It is not clear why mutations in the same gene can cause such variable clinical features. In addition, the molecular etiology of many cases is not identified with current genetic testing approaches. To realize the promise of the Human Genome Project, more genetic causes need to be identified, and the basis for variable clinical presentations needs to be better understood. In this review, we provide information about the overlapping genetic causes of this spectrum of disorders in humans, discuss the influence of genetic background and environment on presentations, and highlight animal models that expand our understanding of how genetic and environmental factors can synergize to generate diverse phenotypes. Evidence for genetic and environmental contributions to this spectrum of disorders is strong.
- 15 July 2026
- Published by The Endocrine Society in Endocrine Reviews
Open AccessGenetic and environmental drivers of craniofacial, brain, and pituitary disorders
Congenital pituitary hormone deficiency (CH) is a rare disorder that usually involves deficient production of growth hormone (GH) and other pituitary hormones. Many cases are syndromic, affecting other aspects of craniofacial development and sometimes other organs. There are many genes implicated in congenital pituitary hormone deficiency, and some of them also cause more severe disorders like septo-optic dysplasia (SOD) and holoprosencephaly (HPE). It is not clear why mutations in the same gene can cause such variable clinical features. In addition, the molecular etiology of many cases is not identified with current genetic testing approaches. To realize the promise of the Human Genome Project, more genetic causes need to be identified, and the basis for variable clinical presentations needs to be better understood. In this review, we provide information about the overlapping genetic causes of this spectrum of disorders in humans, discuss the influence of genetic background and environment on presentations, and highlight animal models that expand our understanding of how genetic and environmental factors can synergize to generate diverse phenotypes. Evidence for genetic and environmental contributions to this spectrum of disorders is strong.
- Open Access
PRC2 complex subunit JARID2 regulates embryonic pituitary stem cell differentiation to the POMC lineage
The pituitary is essential for growth, fertility, and stress response. Pituitary development is defined by transcription factor cascades, but how chromatin landscapes influence it remains elusive. JARID2 is a subunit of polycomb repressive complex 2 repressing transcription by depositing trimethylation on histone 3 lysine 27 (H3K27me3). Here, we established that H3K27me3 levels increase with differentiation in anterior pituitary from embryonic day (E) 10.5 to E14.5 despite ubiquitous Jarid2 mRNA expression. Germline loss of Jarid2 causes pituitary stem cell (PSC) hyperplasia and corticotrope hypoplasia without changing H3K27me3 bulk levels at E14.5. Pituitary-specific loss of Jarid2 with Prop1T2AiCre (Jarid2Pitko/Pitko) exhibits POMC lineage hypoplasia and PSC hyperplasia at E16.5. Pou1f1 or Nr5a1 lineages are not affected by Jarid2 mutation. To determine gene expression and chromatin accessibility changes in Jarid2Pitko/Pitko, we performed single nucleus (sn) multi-omics on E14.5 pituitaries. SnRNAseq revealed potential targets of Jarid2, including Meis2. SnATACseq revealed chromatin reprograming towards PSC retention rather than differentiation. Pax7 is reduced in both modalities in PSC. Together, we show that Jarid2 promotes stemness exit and POMC lineage differentiation, uncovering novel epigenetic regulation of pituitary development.
Open AccessPRC2 complex subunit JARID2 regulates embryonic pituitary stem cell differentiation to the POMC lineage
The pituitary is essential for growth, fertility, and stress response. Pituitary development is defined by transcription factor cascades, but how chromatin landscapes influence it remains elusive. JARID2 is a subunit of polycomb repressive complex 2 repressing transcription by depositing trimethylation on histone 3 lysine 27 (H3K27me3). Here, we established that H3K27me3 levels increase with differentiation in anterior pituitary from embryonic day (E) 10.5 to E14.5 despite ubiquitous Jarid2 mRNA expression. Germline loss of Jarid2 causes pituitary stem cell (PSC) hyperplasia and corticotrope hypoplasia without changing H3K27me3 bulk levels at E14.5. Pituitary-specific loss of Jarid2 with Prop1T2AiCre (Jarid2Pitko/Pitko) exhibits POMC lineage hypoplasia and PSC hyperplasia at E16.5. Pou1f1 or Nr5a1 lineages are not affected by Jarid2 mutation. To determine gene expression and chromatin accessibility changes in Jarid2Pitko/Pitko, we performed single nucleus (sn) multi-omics on E14.5 pituitaries. SnRNAseq revealed potential targets of Jarid2, including Meis2. SnATACseq revealed chromatin reprograming towards PSC retention rather than differentiation. Pax7 is reduced in both modalities in PSC. Together, we show that Jarid2 promotes stemness exit and POMC lineage differentiation, uncovering novel epigenetic regulation of pituitary development.
- 19 February 2026
- Published by Oxford University Press (OUP) in Toxicological Sciences
- Vol. 209 (3)
Acute exposure to diethylhexyl phthalate (DEHP) and diisononyl phthalate (DiNP) impacts pituitary hormones and inflammatory markers, suggesting altered reproductive aging in adult female mice
Phthalates are ubiquitous endocrine-disrupting chemicals whose exposure is associated with accelerated reproductive aging in humans. We focused on the pituitary gland, the source of the gonadotropins: Follicle-stimulating hormone (FSH) and luteinizing hormone (LH). We hypothesized that the common phthalates di-(2-ethylhexyl) phthalate (DEHP) and diisononyl phthalate (DiNP) modulate inflammation in the pituitary and impact gonadotropin expression acutely and during aging. To test this, female CD-1 mice were orally dosed with corn oil or varying concentrations of DEHP and DiNP for 10 days. Pituitary tissues were collected immediately after dosing or 15 months post-dosing, processed, and analyzed by quantitative real-time PCR (qPCR) and immunohistochemistry. We found that acute phthalate exposure did not alter Fshb and Lhb mRNA expression compared with controls, but both DEHP and DiNP reduced FSH immunopositive cell number. Phthalate exposure also decreased Il1b, and increased Il18 and Tnf mRNA levels compared with controls, suggesting an inflammatory imbalance. At 15 months post-dosing, DiNP exposure increased Lhb and Il1b mRNA levels, but repressed Fshb and Nlrp3 mRNA levels compared with controls. Next, using dissociated cultures, we investigated the impact of phthalates and the proinflammatory stimulus lipopolysaccharide (LPS) on inflammation and gonadotropin gene expression directly at the pituitary. Both the DEHP metabolite MEHP and LPS decreased Fshb, but not Lhb mRNA relative to control. MEHP also repressed the induction of Il1b by LPS. Together, these findings suggest that acute exposure to phthalate alters mRNA expression of inflammatory markers and gonadotropins in the pituitary, which could alter the process of reproductive aging.
- 19 February 2026
- Published by Oxford University Press (OUP) in Toxicological Sciences
- Vol. 209 (3)
Acute exposure to diethylhexyl phthalate (DEHP) and diisononyl phthalate (DiNP) impacts pituitary hormones and inflammatory markers, suggesting altered reproductive aging in adult female mice
Phthalates are ubiquitous endocrine-disrupting chemicals whose exposure is associated with accelerated reproductive aging in humans. We focused on the pituitary gland, the source of the gonadotropins: Follicle-stimulating hormone (FSH) and luteinizing hormone (LH). We hypothesized that the common phthalates di-(2-ethylhexyl) phthalate (DEHP) and diisononyl phthalate (DiNP) modulate inflammation in the pituitary and impact gonadotropin expression acutely and during aging. To test this, female CD-1 mice were orally dosed with corn oil or varying concentrations of DEHP and DiNP for 10 days. Pituitary tissues were collected immediately after dosing or 15 months post-dosing, processed, and analyzed by quantitative real-time PCR (qPCR) and immunohistochemistry. We found that acute phthalate exposure did not alter Fshb and Lhb mRNA expression compared with controls, but both DEHP and DiNP reduced FSH immunopositive cell number. Phthalate exposure also decreased Il1b, and increased Il18 and Tnf mRNA levels compared with controls, suggesting an inflammatory imbalance. At 15 months post-dosing, DiNP exposure increased Lhb and Il1b mRNA levels, but repressed Fshb and Nlrp3 mRNA levels compared with controls. Next, using dissociated cultures, we investigated the impact of phthalates and the proinflammatory stimulus lipopolysaccharide (LPS) on inflammation and gonadotropin gene expression directly at the pituitary. Both the DEHP metabolite MEHP and LPS decreased Fshb, but not Lhb mRNA relative to control. MEHP also repressed the induction of Il1b by LPS. Together, these findings suggest that acute exposure to phthalate alters mRNA expression of inflammatory markers and gonadotropins in the pituitary, which could alter the process of reproductive aging.
- Open Access
- 18 October 2024
- Published by Oxford University Press (OUP) in Reproduction
- Vol. 168 (6)
IMPACT OF REAL-LIFE ENVIRONMENTAL EXPOSURES ON REPRODUCTION: Impact of developmental exposures to endocrine-disrupting chemicals on pituitary gland reproductive function
: In brief: Endocrine-disrupting chemicals can impact reproduction by affecting the hypothalamic–pituitary–gonadal axis. This review emphasizes the impact of endocrine-disrupting chemicals on pituitary development and function. The pituitary gland is crucial for regulating many physiological systems, including reproduction. Clear evidence suggests that pituitary function can be impaired by exposure to endocrine-disrupting chemicals (EDCs). Humans and animals are exposed to EDCs throughout life, but exposure during critical periods when the pituitary is developing could have more damaging consequences. In this review, we summarize the development of the pituitary gland, including the impact of hormone signals, and describe how in vivo EDC exposure during development might alter pituitary function. These include changes in pituitary hormone, mRNA, and protein expression levels, as well as pituitary cell number and population balance. We focus on reproductive hormone-producing cells as well as other endocrine and pituitary stem/progenitor cells. We reveal the current gaps in knowledge and suggest future directions in terms of understanding the effects of developmental EDC exposure directly on the pituitary gland.
- 18 October 2024
- Published by Oxford University Press (OUP) in Reproduction
- Vol. 168 (6)
Open AccessIMPACT OF REAL-LIFE ENVIRONMENTAL EXPOSURES ON REPRODUCTION: Impact of developmental exposures to endocrine-disrupting chemicals on pituitary gland reproductive function
: In brief: Endocrine-disrupting chemicals can impact reproduction by affecting the hypothalamic–pituitary–gonadal axis. This review emphasizes the impact of endocrine-disrupting chemicals on pituitary development and function. The pituitary gland is crucial for regulating many physiological systems, including reproduction. Clear evidence suggests that pituitary function can be impaired by exposure to endocrine-disrupting chemicals (EDCs). Humans and animals are exposed to EDCs throughout life, but exposure during critical periods when the pituitary is developing could have more damaging consequences. In this review, we summarize the development of the pituitary gland, including the impact of hormone signals, and describe how in vivo EDC exposure during development might alter pituitary function. These include changes in pituitary hormone, mRNA, and protein expression levels, as well as pituitary cell number and population balance. We focus on reproductive hormone-producing cells as well as other endocrine and pituitary stem/progenitor cells. We reveal the current gaps in knowledge and suggest future directions in terms of understanding the effects of developmental EDC exposure directly on the pituitary gland.
- Open Access
- 21 January 2024
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 586, 112163
Glycoprotein hormone subunit alpha 2 (GPHA2): A pituitary stem cell-expressed gene associated with NOTCH2 signaling
- 21 January 2024
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 586, 112163
Open AccessGlycoprotein hormone subunit alpha 2 (GPHA2): A pituitary stem cell-expressed gene associated with NOTCH2 signaling
- 24 August 2023
- Published by The Endocrine Society in Endocrinology
- Vol. 164 (10)
Characterization of Somatotrope Cell Expansion in Response to GHRH in the Neonatal Mouse Pituitary
In humans and mice, loss-of-function mutations in growth hormone–releasing hormone receptor (GHRHR) cause isolated GH deficiency. The mutant GHRHR mouse model, GhrhrLit/Lit (LIT), exhibits loss of serum GH, but also fewer somatotropes. However, how loss of GHRH signaling affects expansion of stem and progenitor cells giving rise to GH-producing cells is unknown. LIT mice and wild-type littermates were examined for differences in proliferation and gene expression of pituitary lineage markers by quantitative reverse transcription polymerase chain reaction and immunohistochemistry at postnatal day 5 (p5) and 5 weeks. At p5, the LIT mouse shows a global decrease in pituitary proliferation measured by proliferation marker Ki67 and phospho-histone H3. This proliferative defect is seen in a pituitary cell expressing POU1F1 with or without GH. SOX9-positive progenitors show no changes in proliferation in p5 LIT mice. Additionally, the other POU1F1 lineage cells are not decreased in number; rather, we observe an increase in lactotrope cell population as well as messenger RNA for Tshb and Prl. In the 5-week LIT pituitary, the proliferative deficit in POU1F1-expressing cells observed neonatally persists, while the number and proliferative proportion of SOX9 cells do not appear changed. Treatment of cultured pituitary explants with GHRH promotes proliferation of POU1F1-expressing cells, but not GH-positive cells, in a mitogen-activated protein kinase–dependent manner. These findings indicate that hypothalamic GHRH targets proliferation of a POU1F1-positive cell, targeted to the somatotrope lineage, to fine tune their numbers.
- 24 August 2023
- Published by The Endocrine Society in Endocrinology
- Vol. 164 (10)
Characterization of Somatotrope Cell Expansion in Response to GHRH in the Neonatal Mouse Pituitary
In humans and mice, loss-of-function mutations in growth hormone–releasing hormone receptor (GHRHR) cause isolated GH deficiency. The mutant GHRHR mouse model, GhrhrLit/Lit (LIT), exhibits loss of serum GH, but also fewer somatotropes. However, how loss of GHRH signaling affects expansion of stem and progenitor cells giving rise to GH-producing cells is unknown. LIT mice and wild-type littermates were examined for differences in proliferation and gene expression of pituitary lineage markers by quantitative reverse transcription polymerase chain reaction and immunohistochemistry at postnatal day 5 (p5) and 5 weeks. At p5, the LIT mouse shows a global decrease in pituitary proliferation measured by proliferation marker Ki67 and phospho-histone H3. This proliferative defect is seen in a pituitary cell expressing POU1F1 with or without GH. SOX9-positive progenitors show no changes in proliferation in p5 LIT mice. Additionally, the other POU1F1 lineage cells are not decreased in number; rather, we observe an increase in lactotrope cell population as well as messenger RNA for Tshb and Prl. In the 5-week LIT pituitary, the proliferative deficit in POU1F1-expressing cells observed neonatally persists, while the number and proliferative proportion of SOX9 cells do not appear changed. Treatment of cultured pituitary explants with GHRH promotes proliferation of POU1F1-expressing cells, but not GH-positive cells, in a mitogen-activated protein kinase–dependent manner. These findings indicate that hypothalamic GHRH targets proliferation of a POU1F1-positive cell, targeted to the somatotrope lineage, to fine tune their numbers.
- 28 March 2023
- Published by Elsevier in Experimental Neurology
- Vol. 364, 114389
Female-specific pituitary gonadotrope dysregulation in mice with chronic focal epilepsy
- 28 March 2023
- Published by Elsevier in Experimental Neurology
- Vol. 364, 114389
Female-specific pituitary gonadotrope dysregulation in mice with chronic focal epilepsy
- Open Access
Female-Specific Pituitary Hypersensitivity to Gonadotropin-Releasing Hormone in a Mouse Model of Chronic Temporal Lobe Epilepsy
Gonadotropin hormone release from the anterior pituitary is critical to regulating reproductive endocrine function. Clinical evidence has documented that people with epilepsy display altered levels of gonadotropin hormones, both acutely following seizures and chronically. Despite this relationship, pituitary function remains a largely understudied avenue in preclinical epilepsy research. Recently, we showed that females in the intrahippocampal kainic acid (IHKA) mouse model of temporal lobe epilepsy were found to display changes in pituitary expression of gonadotropin hormone and GnRH receptor genes. Circulating gonadotropin hormone levels, however, have yet to be measured in an animal model of epilepsy. Here, we evaluated the circulating levels of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), GnRH receptor ( Gnrhr ) gene expression, and sensitivity to exogenous GnRH in IHKA males and females. Although no changes in overall dynamics of pulsatile patterns of LH release were found in IHKA mice of either sex, estrus vs. diestrus changes in basal and mean LH levels were larger in IHKA females with prolonged, disrupted estrous cycles. In addition, IHKA females displayed increased pituitary sensitivity to GnRH and higher Gnrhr expression. The hypersensitivity to GnRH was observed on diestrus, but not estrus. Chronic seizure severity was not found to be correlated with LH parameters, and FSH levels were unchanged in IHKA mice. These results indicate that although there are changes in pituitary gene expression and sensitivity to GnRH in IHKA females, there may also be compensatory mechanisms that aid in maintaining gonadotropin release in the state of chronic epilepsy in this model.
Open AccessFemale-Specific Pituitary Hypersensitivity to Gonadotropin-Releasing Hormone in a Mouse Model of Chronic Temporal Lobe Epilepsy
Gonadotropin hormone release from the anterior pituitary is critical to regulating reproductive endocrine function. Clinical evidence has documented that people with epilepsy display altered levels of gonadotropin hormones, both acutely following seizures and chronically. Despite this relationship, pituitary function remains a largely understudied avenue in preclinical epilepsy research. Recently, we showed that females in the intrahippocampal kainic acid (IHKA) mouse model of temporal lobe epilepsy were found to display changes in pituitary expression of gonadotropin hormone and GnRH receptor genes. Circulating gonadotropin hormone levels, however, have yet to be measured in an animal model of epilepsy. Here, we evaluated the circulating levels of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), GnRH receptor ( Gnrhr ) gene expression, and sensitivity to exogenous GnRH in IHKA males and females. Although no changes in overall dynamics of pulsatile patterns of LH release were found in IHKA mice of either sex, estrus vs. diestrus changes in basal and mean LH levels were larger in IHKA females with prolonged, disrupted estrous cycles. In addition, IHKA females displayed increased pituitary sensitivity to GnRH and higher Gnrhr expression. The hypersensitivity to GnRH was observed on diestrus, but not estrus. Chronic seizure severity was not found to be correlated with LH parameters, and FSH levels were unchanged in IHKA mice. These results indicate that although there are changes in pituitary gene expression and sensitivity to GnRH in IHKA females, there may also be compensatory mechanisms that aid in maintaining gonadotropin release in the state of chronic epilepsy in this model.
- 22 December 2021
- Published by Elsevier in Reproductive Toxicology
- Vol. 108, 18-27
Prenatal exposure to the phthalate DEHP impacts reproduction-related gene expression in the pituitary
- 22 December 2021
- Published by Elsevier in Reproductive Toxicology
- Vol. 108, 18-27
Prenatal exposure to the phthalate DEHP impacts reproduction-related gene expression in the pituitary